H. Lundbeck A/S
CPH: HLUN-B.CO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Copenhagen
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Charl van Zyl
- Employees
- 5,707
- Headquarters
- Valby, Denmark
- IPO year
- 2022
- Market cap
- DKK 34.2B
- Website
- https://www.lundbeck.com
Loading HLUN-B…
Loading profile data…Frequently asked questions about HLUN-B
What does H. Lundbeck A/S (HLUN-B.CO) do?
H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depressi...
Where does HLUN-B.CO trade?
H. Lundbeck A/S (HLUN-B.CO) trades on the NASDAQ Copenhagen.
What sector is HLUN-B.CO in?
H. Lundbeck A/S (HLUN-B.CO) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of H. Lundbeck A/S?
Charl van Zyl is the chief executive officer of H. Lundbeck A/S (HLUN-B.CO).
Where is H. Lundbeck A/S headquartered?
H. Lundbeck A/S is headquartered in Denmark.
Does HLUN-B.CO pay a dividend?
Yes — H. Lundbeck A/S (HLUN-B.CO) paid a trailing twelve-month dividend of DKK 1.15 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did HLUN-B.CO go public?
H. Lundbeck A/S (HLUN-B.CO) completed its initial public offering in 2022.